{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:46:19Z","timestamp":1793843179075,"version":"4.6.1"},"reference-count":217,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-025-05417-z","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T01:57:04Z","timestamp":1763517424000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Targeted Nanoparticles for Drug Delivery Across the Blood\u2013Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review"],"prefix":"10.1007","volume":"63","author":[{"given":"Urszula","family":"Kochman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Sitka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Ku\u017aniar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Czaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Kozubek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Aleksander","family":"Besz\u0142ej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Leszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"4","key":"5417_CR1","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/alz.13025","volume":"19","author":"Alzheimer\u2019s disease facts and figures","year":"2023","unstructured":"Alzheimer\u2019s disease facts and figures (2023) Alzheimers Dement 19(4):1598\u20131695. https:\/\/doi.org\/10.1002\/alz.13025","journal-title":"Alzheimers Dement"},{"key":"5417_CR2","unstructured":"FastStats - Leading Causes of Death [Internet]. CDC; [cited 2025 Jul 12]. Available from: https:\/\/www.cdc.gov\/nchs\/fastats\/leading-causes-of-death.htm"},{"issue":"1","key":"5417_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","volume":"37","author":"NJ Abbott","year":"2010","unstructured":"Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37(1):13\u201325. https:\/\/doi.org\/10.1016\/j.nbd.2009.07.030","journal-title":"Neurobiol Dis"},{"issue":"2","key":"5417_CR4","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neuron.2008.01.003","volume":"57","author":"BV Zlokovic","year":"2008","unstructured":"Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57(2):178\u2013201. https:\/\/doi.org\/10.1016\/j.neuron.2008.01.003","journal-title":"Neuron"},{"issue":"3","key":"5417_CR5","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/0014-4886(87)90024-6","volume":"97","author":"BK Armstrong","year":"1987","unstructured":"Armstrong BK, Robinson PJ, Rapoport SI (1987) Size-dependent blood-brain barrier opening demonstrated with [14C]sucrose and a 200,000-Da [3H]dextran. Exp Neurol 97(3):686\u2013696. https:\/\/doi.org\/10.1016\/0014-4886(87)90024-6","journal-title":"Exp Neurol"},{"issue":"1","key":"5417_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ultrasmedbio.2009.08.006","volume":"36","author":"JJ Choi","year":"2010","unstructured":"Choi JJ, Wang S, Tung YS, Morrison B, Konofagou EE (2010) Molecules of various pharmacologically-relevant sizes can cross the ultrasound-induced blood-brain barrier opening in vivo. Ultrasound Med Biol 36(1):58\u201367. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2009.08.006","journal-title":"Ultrasound Med Biol"},{"issue":"10","key":"5417_CR7","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/jcbfm.2013.135","volume":"33","author":"MA Erickson","year":"2013","unstructured":"Erickson MA, Banks WA (2013) Blood-brain barrier dysfunction as a cause and consequence of Alzheimer\u2019s disease. J Cereb Blood Flow Metab 33(10):1500\u20131513. https:\/\/doi.org\/10.1038\/jcbfm.2013.135","journal-title":"J Cereb Blood Flow Metab"},{"key":"5417_CR8","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1146\/annurev-pharmtox-010814-124852","volume":"55","author":"JM Lajoie","year":"2015","unstructured":"Lajoie JM, Shusta EV (2015) Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. Annu Rev Pharmacol Toxicol 55:613\u2013631. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010814-124852","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"5417_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","volume":"235","author":"C Saraiva","year":"2016","unstructured":"Saraiva C, Pra\u00e7a C, Ferreira R, Santos T, Ferreira L, Bernardino L (2016) Nanoparticle-mediated brain drug delivery: overcoming blood\u2013brain barrier to treat neurodegenerative diseases. J Control Release 235:34\u201347. https:\/\/doi.org\/10.1016\/j.jconrel.2016.05.044","journal-title":"J Control Release"},{"issue":"84","key":"5417_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002230","volume":"3","author":"YJ Yu","year":"2011","unstructured":"Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y et al (2011) Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 3(84):84ra44. https:\/\/doi.org\/10.1126\/scitranslmed.3002230","journal-title":"Sci Transl Med"},{"issue":"4","key":"5417_CR11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3390\/polym14040763","volume":"14","author":"S Habib","year":"2022","unstructured":"Habib S, Singh M (2022) Angiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review. Polymers (Basel) 14(4):763. https:\/\/doi.org\/10.3390\/polym14040763","journal-title":"Polymers (Basel)"},{"key":"5417_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2022.112999","volume":"221","author":"MI Teixeira","year":"2023","unstructured":"Teixeira MI, Lopes CM, Amaral MH, Costa PC (2023) Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): a current overview of active targeting in brain diseases. Colloids Surf B Biointerfaces 221:112999. https:\/\/doi.org\/10.1016\/j.colsurfb.2022.112999","journal-title":"Colloids Surf B Biointerfaces"},{"key":"5417_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk JS, Xu Q, Kim N, Hanes J, Ensign LM (2016) PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 99:28\u201351. https:\/\/doi.org\/10.1016\/j.addr.2015.09.012","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"5417_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.molimm.2005.03.005","volume":"43","author":"C Salvador-Morales","year":"2006","unstructured":"Salvador-Morales C, Flahaut E, Sim E, Sloan J, Green MLH, Sim RB (2006) Complement activation and protein adsorption by carbon nanotubes. Mol Immunol 43(3):193\u2013201. https:\/\/doi.org\/10.1016\/j.molimm.2005.03.005","journal-title":"Mol Immunol"},{"issue":"9","key":"5417_CR15","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1021\/acs.chemrev.5b00589","volume":"116","author":"K Ulbrich","year":"2016","unstructured":"Ulbrich K, Hol\u00e1 K, \u0160ubr V, Bakandritsos A, Tu\u010dek J, Zbo\u0159il R (2016) Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies. Chem Rev 116(9):5338\u20135431. https:\/\/doi.org\/10.1021\/acs.chemrev.5b00589","journal-title":"Chem Rev"},{"issue":"7","key":"5417_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.addr.2011.04.001","volume":"64","author":"WA Banks","year":"2011","unstructured":"Banks WA (2011) Drug Delivery to the Brain in Alzheimer\u2019s Disease: Consideration of the Blood-brain Barrier. Adv Drug Deliv Rev 64(7):629\u2013639. https:\/\/doi.org\/10.1016\/j.addr.2011.04.001","journal-title":"Adv Drug Deliv Rev"},{"key":"5417_CR17","doi-asserted-by":"publisher","unstructured":"[Zhang C, Tanzi RE (2012) Natural Modulators of Amyloid-Beta Precursor Protein Processing. Curr Alzheimer Res 9(9):1101\u20139 https:\/\/doi.org\/10.2174\/156720512803251327","DOI":"10.2174\/156720512803251327"},{"key":"5417_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","volume":"34","author":"RJ O\u2019Brien","year":"2011","unstructured":"O\u2019Brien RJ, Wong PC (2011) Amyloid precursor protein processing and Alzheimer\u2019s disease. Annu Rev Neurosci 34:185\u2013204. https:\/\/doi.org\/10.1146\/annurev-neuro-061010-113613","journal-title":"Annu Rev Neurosci"},{"issue":"24","key":"5417_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249591","volume":"21","author":"YJ Kang","year":"2020","unstructured":"Kang YJ, Diep YN, Tran M, Cho H (2020) Therapeutic targeting strategies for early- to late-staged Alzheimer\u2019s disease. Int J Mol Sci 21(24):9591. https:\/\/doi.org\/10.3390\/ijms21249591","journal-title":"Int J Mol Sci"},{"issue":"6","key":"5417_CR20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/0197-4580(93)90010-R","volume":"14","author":"DA Bennett","year":"1993","unstructured":"Bennett DA, Cochran EJ, Saper CB, Leverenz JB, Gilley DW, Wilson RS (1993) Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer\u2019s disease. Neurobiol Aging 14(6):589\u2013596. https:\/\/doi.org\/10.1016\/0197-4580(93)90010-R","journal-title":"Neurobiol Aging"},{"issue":"2","key":"5417_CR21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1006\/exnr.1999.7112","volume":"158","author":"J Wang","year":"1999","unstructured":"Wang J, Dickson DW, Trojanowski JQ, Lee VMY (1999) The levels of soluble versus insoluble brain Abeta distinguish Alzheimer\u2019s disease from normal and pathologic aging. Exp Neurol 158(2):328\u2013337. https:\/\/doi.org\/10.1006\/exnr.1999.7112","journal-title":"Exp Neurol"},{"issue":"2","key":"5417_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/alzrt110","volume":"4","author":"S Weggen","year":"2012","unstructured":"Weggen S, Beher D (2012) Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer\u2019s disease. Alzheimers Res Ther 4(2):9. https:\/\/doi.org\/10.1186\/alzrt110","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"5417_CR23","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.04.23","volume":"6","author":"YL Gao","year":"2018","unstructured":"Gao YL, Wang N, Sun FR, Cao XP, Zhang W, Yu JT (2018) Tau in neurodegenerative disease. Ann Transl Med 6(10):175. https:\/\/doi.org\/10.21037\/atm.2018.04.23","journal-title":"Ann Transl Med"},{"issue":"3","key":"5417_CR24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.celrep.2018.03.022","volume":"23","author":"SL Esp\u00edndola","year":"2018","unstructured":"Esp\u00edndola SL, Damianich A, Alvarez RJ, Sartor M, Belforte JE, Ferrario JE et al (2018) Modulation of Tau Isoforms Imbalance Precludes Tau Pathology and Cognitive Decline in a Mouse Model of Tauopathy. Cell Rep 23(3):709\u2013715. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.022","journal-title":"Cell Rep"},{"issue":"9","key":"5417_CR25","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s11095-007-9305-6","volume":"24","author":"AR Jones","year":"2007","unstructured":"Jones AR, Shusta EV (2007) Blood-Brain Barrier Transport of Therapeutics via Receptor-Mediation. Pharm Res 24(9):1759\u20131771. https:\/\/doi.org\/10.1007\/s11095-007-9305-6","journal-title":"Pharm Res"},{"issue":"5","key":"5417_CR26","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71(5):362\u2013381. https:\/\/doi.org\/10.1097\/NEN.0b013e31825018f7","journal-title":"J Neuropathol Exp Neurol"},{"key":"5417_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fnins.2018.00025","volume":"12","author":"F Kametani","year":"2018","unstructured":"Kametani F, Hasegawa M (2018) Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer\u2019s disease. Front Neurosci 12:25. https:\/\/doi.org\/10.3389\/fnins.2018.00025","journal-title":"Front Neurosci"},{"issue":"5","key":"5417_CR28","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1093\/brain\/awaa078","volume":"143","author":"M Malpetti","year":"2020","unstructured":"Malpetti M, Kievit RA, Passamonti L, Simon Jones P, Tsvetanov KA, Rittman T et al (2020) Microglial activation and tau burden predict cognitive decline in Alzheimer\u2019s disease. Brain 143(5):1588\u20131602. https:\/\/doi.org\/10.1093\/brain\/awaa078","journal-title":"Brain"},{"issue":"1","key":"5417_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8416763","volume":"2017","author":"G Pizzino","year":"2017","unstructured":"Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V et al (2017) Oxidative stress: harms and benefits for human health. Oxid Med Cell Longev 2017(1):8416763. https:\/\/doi.org\/10.1155\/2017\/8416763","journal-title":"Oxid Med Cell Longev"},{"issue":"5","key":"5417_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3892\/br.2016.630","volume":"4","author":"WJ Huang","year":"2016","unstructured":"Huang WJ, Zhang X, Chen WW (2016) Role of oxidative stress in Alzheimer\u2019s disease. Biomed Rep 4(5):519\u2013522. https:\/\/doi.org\/10.3892\/br.2016.630. ((cited 2025-07-13))","journal-title":"Biomed Rep"},{"issue":"3","key":"5417_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033552","volume":"7","author":"TJA Craddock","year":"2012","unstructured":"Craddock TJA, Tuszynski JA, Chopra D, Casey N, Goldstein LE, Hameroff SR et al (2012) The zinc dyshomeostasis hypothesis of Alzheimer\u2019s disease. PLoS ONE 7(3):e33552. https:\/\/doi.org\/10.1371\/journal.pone.0033552","journal-title":"PLoS ONE"},{"key":"5417_CR32","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","volume":"4","author":"JW Kinney","year":"2018","unstructured":"Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT (2018) Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimers Dement (N Y) 4:575\u2013590. https:\/\/doi.org\/10.1016\/j.trci.2018.06.014","journal-title":"Alzheimers Dement (N Y)"},{"issue":"2","key":"5417_CR33","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1365-2567.2009.03225.x","volume":"129","author":"S Amor","year":"2010","unstructured":"Amor S, Puentes F, Baker D, Van Der Valk P (2010) Inflammation in neurodegenerative diseases. Immunology 129(2):154\u2013169. https:\/\/doi.org\/10.1111\/j.1365-2567.2009.03225.x","journal-title":"Immunology"},{"issue":"9","key":"5417_CR34","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1172\/JCI90637","volume":"127","author":"H Sarlus","year":"2017","unstructured":"Sarlus H, Heneka MT (2017) Microglia in Alzheimer\u2019s disease. J Clin Invest 127(9):3240\u20133249. https:\/\/doi.org\/10.1172\/JCI90637","journal-title":"J Clin Invest"},{"issue":"2","key":"5417_CR35","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s12035-014-8657-1","volume":"50","author":"F Brosseron","year":"2014","unstructured":"Brosseron F, Krauthausen M, Kummer M, Heneka MT (2014) Body fluid cytokine levels in mild cognitive impairment and Alzheimer\u2019s disease: a comparative overview. Mol Neurobiol 50(2):534\u2013544. https:\/\/doi.org\/10.1007\/s12035-014-8657-1","journal-title":"Mol Neurobiol"},{"issue":"6","key":"5417_CR36","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1523\/JNEUROSCI.18-06-02161.1998","volume":"18","author":"DT Weldon","year":"1998","unstructured":"Weldon DT, Rogers SD, Ghilardi JR, Finke MP, Cleary JP, O\u2019Hare E et al (1998) Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci 18(6):2161\u20132173. https:\/\/doi.org\/10.1523\/JNEUROSCI.18-06-02161.1998","journal-title":"J Neurosci"},{"issue":"8","key":"5417_CR37","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1038\/s41380-022-01637-0","volume":"27","author":"V Haage","year":"2022","unstructured":"Haage V, De Jager PL (2022) Neuroimmune contributions to Alzheimer\u2019s disease: a focus on human data. Mol Psychiatry 27(8):3164\u20133181. https:\/\/doi.org\/10.1038\/s41380-022-01637-0","journal-title":"Mol Psychiatry"},{"issue":"5","key":"5417_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010830","volume":"5","author":"Y Fisher","year":"2010","unstructured":"Fisher Y, Nemirovsky A, Baron R, Monsonego A (2010) T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer\u2019s disease. PLoS ONE 5(5):e10830. https:\/\/doi.org\/10.1371\/journal.pone.0010830","journal-title":"PLoS ONE"},{"issue":"1\u20132","key":"5417_CR39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0165-5728(01)00520-8","volume":"124","author":"T Togo","year":"2002","unstructured":"Togo T, Akiyama H, Iseki E, Kondo H, Ikeda K, Kato M et al (2002) Occurrence of T cells in the brain of Alzheimer\u2019s disease and other neurological diseases. J Neuroimmunol 124(1\u20132):83\u201392. https:\/\/doi.org\/10.1016\/S0165-5728(01)00520-8","journal-title":"J Neuroimmunol"},{"issue":"1","key":"5417_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/JAD-150001","volume":"48","author":"S S\u00f6llvander","year":"2015","unstructured":"S\u00f6llvander S, Ekholm-Pettersson F, Brundin RM, Westman G, Kilander L, Paulie S et al (2015) Increased number of plasma B cells producing autoantibodies against A\u03b242 protofibrils in Alzheimer\u2019s disease. J Alzheimers Dis 48(1):63\u201372. https:\/\/doi.org\/10.3233\/JAD-150001","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"5417_CR41","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/s41591-020-0891-2","volume":"26","author":"JW Blanchard","year":"2020","unstructured":"Blanchard JW, Bula M, Davila-Velderrain J, Akay LA, Zhu L, Frank A et al (2020) Reconstruction of the human blood-brain barrier in vitro reveals a pathogenic mechanism of APOE4 in pericytes. Nat Med 26(6):952\u2013963. https:\/\/doi.org\/10.1038\/s41591-020-0891-2","journal-title":"Nat Med"},{"issue":"1","key":"5417_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-019-1453-0","volume":"16","author":"DA Dionisio-Santos","year":"2019","unstructured":"Dionisio-Santos DA, Olschowka JA, O\u2019Banion MK (2019) Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer\u2019s disease. J Neuroinflammation 16(1):1\u201313. https:\/\/doi.org\/10.1186\/s12974-019-1453-0","journal-title":"J Neuroinflammation"},{"issue":"1","key":"5417_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12987-020-00196-2","volume":"17","author":"P Sol\u00e1r","year":"2020","unstructured":"Sol\u00e1r P, Zamani A, Kub\u00ed\u010dkov\u00e1 L, Dubov\u00fd P, Joukal M (2020) Choroid plexus and the blood\u2013cerebrospinal fluid barrier in disease. Fluids Barriers CNS 17(1):1\u201329. https:\/\/doi.org\/10.1186\/s12987-020-00196-2","journal-title":"Fluids Barriers CNS"},{"issue":"1","key":"5417_CR44","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/S1474-4422(07)70333-4","volume":"7","author":"E Neuwelt","year":"2008","unstructured":"Neuwelt E, Abbott NJ, Abrey L, Banks WA, Blakley B, Davis T et al (2008) Strategies to advance translational research into brain barriers. Lancet Neurol 7(1):84\u201396. https:\/\/doi.org\/10.1016\/S1474-4422(07)70333-4","journal-title":"Lancet Neurol"},{"key":"5417_CR45","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.peptides.2015.05.014","volume":"72","author":"WA Banks","year":"2015","unstructured":"Banks WA (2015) Peptides and the blood\u2013brain barrier. Peptides 72:16\u201319. https:\/\/doi.org\/10.1016\/j.peptides.2015.05.014","journal-title":"Peptides"},{"issue":"1","key":"5417_CR46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1743-8454-5-10","volume":"5","author":"CE Johanson","year":"2008","unstructured":"Johanson CE, Duncan JA, Klinge PM, Brinker T, Stopa EG, Silverberg GD (2008) Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res 5(1):10. https:\/\/doi.org\/10.1186\/1743-8454-5-10","journal-title":"Cerebrospinal Fluid Res"},{"key":"5417_CR47","doi-asserted-by":"publisher","first-page":"1258640","DOI":"10.3389\/fnagi.2023.1258640","volume":"15","author":"Y Chen","year":"2023","unstructured":"Chen Y, He Y, Han J, Wei W, Chen F (2023) Blood\u2013brain barrier dysfunction and Alzheimer\u2019s disease: associations, pathogenic mechanisms, and therapeutic potential. Front Aging Neurosci 15:1258640. https:\/\/doi.org\/10.3389\/fnagi.2023.1258640","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"5417_CR48","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00401-018-1860-8","volume":"135","author":"S Liebner","year":"2018","unstructured":"Liebner S, Dijkhuizen RM, Reiss Y, Plate KH, Agalliu D, Constantin G (2018) Functional morphology of the blood\u2013brain barrier in health and disease. Acta Neuropathol 135(3):311\u2013336. https:\/\/doi.org\/10.1007\/s00401-018-1860-8","journal-title":"Acta Neuropathol"},{"issue":"5","key":"5417_CR49","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.14336\/AD.2022.0130","volume":"13","author":"QQ Tao","year":"2022","unstructured":"Tao QQ, Lin RR, Chen YH, Wu ZY (2022) Discerning the role of blood brain barrier dysfunction in Alzheimer\u2019s disease. Aging Dis 13(5):1391\u20131404. https:\/\/doi.org\/10.14336\/AD.2022.0130","journal-title":"Aging Dis"},{"issue":"22","key":"5417_CR50","doi-asserted-by":"publisher","first-page":"16288","DOI":"10.3390\/ijms242216288","volume":"24","author":"AE Alkhalifa","year":"2023","unstructured":"Alkhalifa AE, Al-Ghraiybah NF, Odum J, Rostagno AA, Ghiso J, Alkhalifa AE et al (2023) Blood\u2013brain barrier breakdown in Alzheimer\u2019s disease: mechanisms and targeted strategies. Int J Mol Sci 24(22):16288. https:\/\/doi.org\/10.3390\/ijms242216288","journal-title":"Int J Mol Sci"},{"issue":"9","key":"5417_CR51","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s12031-022-02052-4","volume":"72","author":"M Cai","year":"2022","unstructured":"Cai M, Chen S, Du Y, Li S, Dong P, Wang L et al (2022) The role of blood\u2013brain barrier dysfunction in mild cognitive impairment: a scientometric and visualization analysis from 2000 to 2021. J Mol Neurosci 72(9):1977\u20131989. https:\/\/doi.org\/10.1007\/s12031-022-02052-4","journal-title":"J Mol Neurosci"},{"issue":"2","key":"5417_CR52","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","volume":"25","author":"DA Nation","year":"2019","unstructured":"Nation DA, Sweeney MD, Montagne A, Sagare AP, D\u2019Orazio LM, Pachicano M et al (2019) Blood\u2013brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med 25(2):270\u2013276. https:\/\/doi.org\/10.1038\/s41591-018-0297-y","journal-title":"Nat Med"},{"issue":"9","key":"5417_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18091965","volume":"18","author":"Y Yamazaki","year":"2017","unstructured":"Yamazaki Y, Kanekiyo T (2017) Blood-brain barrier dysfunction and the pathogenesis of Alzheimer\u2019s disease. Int J Mol Sci 18(9):1965. https:\/\/doi.org\/10.3390\/ijms18091965","journal-title":"Int J Mol Sci"},{"key":"5417_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108119","volume":"234","author":"G Nehra","year":"2022","unstructured":"Nehra G, Bauer B, Hartz AMS (2022) Blood-brain barrier leakage in Alzheimer\u2019s disease: from discovery to clinical relevance. Pharmacol Ther 234:108119. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108119","journal-title":"Pharmacol Ther"},{"issue":"3","key":"5417_CR55","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","volume":"14","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Sagare AP, Zlokovic BV (2018) Blood\u2013brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol 14(3):133\u2013150","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"5417_CR56","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s44161-021-00014-4","volume":"1","author":"G Barisano","year":"2022","unstructured":"Barisano G, Montagne A, Kisler K, Schneider JA, Wardlaw JM, Zlokovic BV (2022) Blood\u2013brain barrier link to human cognitive impairment and Alzheimer\u2019s disease. Nat Cardiovasc Res 1(2):108\u2013115. https:\/\/doi.org\/10.1038\/s44161-021-00014-4","journal-title":"Nat Cardiovasc Res"},{"key":"5417_CR57","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1146\/annurev-bioeng-082120-042814","volume":"23","author":"C Hajal","year":"2021","unstructured":"Hajal C, Le Roi B, Kamm RD, Maoz BM (2021) Biology and models of the blood-brain barrier. Annu Rev Biomed Eng 23:359\u2013384. https:\/\/doi.org\/10.1146\/annurev-bioeng-082120-042814","journal-title":"Annu Rev Biomed Eng"},{"issue":"4","key":"5417_CR58","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1172\/JCI452","volume":"102","author":"JB Mackic","year":"1998","unstructured":"Mackic JB, Stins M, McComb JG, Calero M, Ghiso J, Kim KS et al (1998) Human blood-brain barrier receptors for Alzheimer\u2019s amyloid-beta 1\u201340. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J Clin Invest 102(4):734\u2013743. https:\/\/doi.org\/10.1172\/JCI452","journal-title":"J Clin Invest"},{"key":"5417_CR59","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.29595","volume":"6","author":"J Robert","year":"2017","unstructured":"Robert J, Button EB, Yuen B, Gilmour M, Kang K, Bahrabadi A et al (2017) Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels. Elife 6:e29595. https:\/\/doi.org\/10.7554\/eLife.29595","journal-title":"Elife"},{"issue":"20","key":"5417_CR60","doi-asserted-by":"publisher","first-page":"1900962","DOI":"10.1002\/advs.201900962","volume":"6","author":"Y Shin","year":"2019","unstructured":"Shin Y, Choi SH, Kim E, Bylykbashi E, Kim JA, Chung S et al (2019) Blood-brain barrier dysfunction in a 3D in vitro model of Alzheimer\u2019s disease. Adv Sci (Weinh) 6(20):1900962. https:\/\/doi.org\/10.1002\/advs.201900962","journal-title":"Adv Sci (Weinh)"},{"key":"5417_CR61","doi-asserted-by":"publisher","first-page":"127938","DOI":"10.1016\/j.molliq.2023.127938","volume":"433","author":"G Pramoda","year":"2025","unstructured":"Pramoda G, Verma RK, Kesharwani P, Shukla R (2025) Surface-functionalized nanoparticles for targeted drug delivery across the blood-brain barrier: advances and challenges in neurodegenerative disease therapy. J Mol Liq 433:127938. https:\/\/doi.org\/10.1016\/j.molliq.2023.127938","journal-title":"J Mol Liq"},{"issue":"8","key":"5417_CR62","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.drudis.2021.03.007","volume":"26","author":"R Shukla","year":"2021","unstructured":"Shukla R, Singh A, Handa M, Flora SJS, Kesharwani P (2021) Nanotechnological approaches for targeting amyloid-\u03b2 aggregation with potential for neurodegenerative disease therapy and diagnosis. Drug Discov Today 26(8):1972\u20131979. https:\/\/doi.org\/10.1016\/j.drudis.2021.03.007","journal-title":"Drug Discov Today"},{"key":"5417_CR63","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5c00386","author":"S Kumar","year":"2025","unstructured":"Kumar S, Yadav A, Verma RK, Kumar A, Gupta PK, Shukla R (2025) Intranasal therapeutics for neurodegenerative disorders: overcoming the blood-brain barrier with smart formulations and devices. Mol Pharm. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c00386","journal-title":"Mol Pharm"},{"issue":"18","key":"5417_CR64","doi-asserted-by":"publisher","first-page":"14044","DOI":"10.3390\/ijms241814044","volume":"24","author":"Z Zhou","year":"2023","unstructured":"Zhou Z, Kihara AH, Puranik N, Yadav D, Song M (2023) Advancements in the application of nanomedicine in alzheimer\u2019s disease: a therapeutic perspective. Int J Mol Sci 24(18):14044. https:\/\/doi.org\/10.3390\/ijms241814044","journal-title":"Int J Mol Sci"},{"issue":"35","key":"5417_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202003054","volume":"30","author":"S Mukherjee","year":"2020","unstructured":"Mukherjee S, Madamsetty VS, Bhattacharya D, Roy Chowdhury S, Paul MK, Mukherjee A (2020) Recent advancements of nanomedicine in neurodegenerative disorders theranostics. Adv Funct Mater 30(35):2003054. https:\/\/doi.org\/10.1002\/adfm.202003054","journal-title":"Adv Funct Mater"},{"issue":"5","key":"5417_CR66","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3109\/1547691X.2016.1167073","volume":"13","author":"G Ghalamfarsa","year":"2016","unstructured":"Ghalamfarsa G, Hojjat-Farsangi M, Mohammadnia-Afrouzi M, Anvari E, Farhadi S, Yousefi M et al (2016) Application of nanomedicine for crossing the blood-brain barrier: Theranostic opportunities in multiple sclerosis. J Immunotoxicol 13(5):603\u2013619. https:\/\/doi.org\/10.3109\/1547691X.2016.1167073","journal-title":"J Immunotoxicol"},{"issue":"3","key":"5417_CR67","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3390\/nano13030464","volume":"13","author":"TM Joseph","year":"2023","unstructured":"Joseph TM, Kar Mahapatra D, Esmaeili A, Piszczyk \u0141, Hasanin MS, Kattali M et al (2023) Nanoparticles: taking a unique position in medicine. Nanomaterials (Basel) 13(3):464. https:\/\/doi.org\/10.3390\/nano13030464","journal-title":"Nanomaterials (Basel)"},{"key":"5417_CR68","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3389\/fnins.2020.00498","volume":"14","author":"S Naqvi","year":"2020","unstructured":"Naqvi S, Panghal A, Flora SJS (2020) Nanotechnology: a promising approach for delivery of neuroprotective drugs. Front Neurosci 14:498. https:\/\/doi.org\/10.3389\/fnins.2020.00498","journal-title":"Front Neurosci"},{"issue":"3","key":"5417_CR69","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3390\/pharmaceutics14030609","volume":"14","author":"D Lombardo","year":"2022","unstructured":"Lombardo D, Kiselev MA (2022) Methods of liposomes preparation: formation and control factors of versatile nanocarriers for biomedical and nanomedicine application. Pharmaceutics 14(3):609. https:\/\/doi.org\/10.3390\/pharmaceutics14030609","journal-title":"Pharmaceutics"},{"issue":"1","key":"5417_CR70","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ijpharm.2013.01.032","volume":"448","author":"MS Mufamadi","year":"2013","unstructured":"Mufamadi MS, Choonara YE, Kumar P, Modi G, Naidoo D, Van Vuuren S et al (2013) Ligand-functionalized nanoliposomes for targeted delivery of galantamine. Int J Pharm 448(1):267\u2013281. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.01.032","journal-title":"Int J Pharm"},{"issue":"1","key":"5417_CR71","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1080\/10717544.2017.1297819","volume":"24","author":"SN El-Helaly","year":"2017","unstructured":"El-Helaly SN, Elbary AA, Kassem MA, El-Nabarawi MA (2017) Electrosteric stealth Rivastigmine loaded liposomes for brain targeting: preparation, characterization, ex vivo, bio-distribution and in vivo pharmacokinetic studies. Drug Deliv 24(1):692\u2013700. https:\/\/doi.org\/10.1080\/10717544.2017.1297819","journal-title":"Drug Deliv"},{"issue":"1\u20132","key":"5417_CR72","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ijpharm.2013.06.050","volume":"452","author":"ZZ Yang","year":"2013","unstructured":"Yang ZZ, Zhang YQ, Wang ZZ, Wu K, Lou JN, Qi XR (2013) Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int J Pharm 452(1\u20132):344\u2013354. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.06.050","journal-title":"Int J Pharm"},{"key":"5417_CR73","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/DDDT.S95582","volume":"10","author":"AK Al Asmari","year":"2016","unstructured":"Al Asmari AK, Ullah Z, Tariq M, Fatani A (2016) Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Des Devel Ther 10:205\u2013215. https:\/\/doi.org\/10.2147\/DDDT.S95582","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"5417_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13081183","volume":"13","author":"MK Satapathy","year":"2021","unstructured":"Satapathy MK, Yen TL, Jan JS, Tang RD, Wang JY, Taliyan R et al (2021) Solid lipid nanoparticles (SLNs): an advanced drug delivery system targeting brain through BBB. Pharmaceutics 13(8):1183. https:\/\/doi.org\/10.3390\/pharmaceutics13081183","journal-title":"Pharmaceutics"},{"issue":"2\u20133","key":"5417_CR75","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/s0169-409x(00)00105-3","volume":"47","author":"W Mehnert","year":"2001","unstructured":"Mehnert W, M\u00e4der K (2001) Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 47(2\u20133):165\u2013196. https:\/\/doi.org\/10.1016\/s0169-409x(00)00105-3","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"5417_CR76","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3390\/pharmaceutics15030708","volume":"15","author":"Y Seo","year":"2023","unstructured":"Seo Y, Lim H, Park H, Yu J, An J, Yoo HY et al (2023) Recent progress of lipid nanoparticles-based lipophilic drug delivery: focus on surface modifications. Pharmaceutics 15(3):708. https:\/\/doi.org\/10.3390\/pharmaceutics15030708","journal-title":"Pharmaceutics"},{"issue":"9","key":"5417_CR77","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jsps.2021.06.009","volume":"29","author":"M Elmowafy","year":"2021","unstructured":"Elmowafy M, Al-Sanea MM (2021) Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies. Saudi Pharm J 29(9):999\u20131012. https:\/\/doi.org\/10.1016\/j.jsps.2021.06.009","journal-title":"Saudi Pharm J"},{"issue":"7","key":"5417_CR78","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.3390\/molecules27072315","volume":"27","author":"E Musielak","year":"2022","unstructured":"Musielak E, Feliczak-Guzik A, Nowak I (2022) Optimization of the Conditions of Solid Lipid Nanoparticles (SLN) Synthesis. Molecules 27(7):2315. https:\/\/doi.org\/10.3390\/molecules27072315","journal-title":"Molecules"},{"key":"5417_CR79","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.2147\/IJN.S400433","volume":"18","author":"MK Shehata","year":"2023","unstructured":"Shehata MK, Ismail AA, Kamel MA (2023) Combined Donepezil with Astaxanthin via Nanostructured Lipid Carriers Effective Delivery to Brain for Alzheimer\u2019s Disease in Rat Model. Int J Nanomedicine 18:4193\u20134227. https:\/\/doi.org\/10.2147\/IJN.S400433","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"5417_CR80","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-023-01525-8","volume":"9","author":"J Zhang","year":"2024","unstructured":"Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L (2024) Recent advances in Alzheimer\u2019s disease: Mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther 9(1):68. https:\/\/doi.org\/10.1038\/s41392-023-01525-8","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"5417_CR81","doi-asserted-by":"publisher","first-page":"2002794","DOI":"10.1002\/advs.202002794","volume":"8","author":"W Zhang","year":"2021","unstructured":"Zhang W, Mehta A, Tong Z, Esser L, Voelcker NH (2021) Development of Polymeric Nanoparticles for Blood-Brain Barrier Transfer-Strategies and Challenges. Adv Sci (Weinh) 8(10):2002794. https:\/\/doi.org\/10.1002\/advs.202002794","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"5417_CR82","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s40001-024-00633-0","volume":"29","author":"I Iqbal","year":"2024","unstructured":"Iqbal I, Saqib F, Mubarak Z, Latif MF, Wahid M, Nasir B et al (2024) Alzheimer\u2019s disease and drug delivery across the blood-brain barrier: approaches and challenges. Eur J Med Res 29(1):313. https:\/\/doi.org\/10.1186\/s40001-024-00633-0","journal-title":"Eur J Med Res"},{"key":"5417_CR83","unstructured":"Nanoparticles for direct nose-to-brain delivery of drugs. Europe PMC. Available from: https:\/\/europepmc.org\/article\/med\/19555750"},{"key":"5417_CR84","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.brainres.2008.01.051","volume":"1200","author":"B Wilson","year":"2008","unstructured":"Wilson B, Samanta MK, Santhi K, Kumar KPS, Paramakrishnan N, Suresh B (2008) Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer\u2019s disease. Brain Res 1200:159\u2013168. https:\/\/doi.org\/10.1016\/j.brainres.2008.01.051","journal-title":"Brain Res"},{"issue":"42","key":"5417_CR85","doi-asserted-by":"publisher","first-page":"24539","DOI":"10.1039\/C9RA02225B","volume":"9","author":"HR El-Seedi","year":"2019","unstructured":"El-Seedi HR, El-Shabasy RM, Khalifa SAM, Saeed A, Shah A, Shah R et al (2019) Metal nanoparticles fabricated by green chemistry using natural extracts: biosynthesis, mechanisms, and applications. RSC Adv 9(42):24539\u201324559. https:\/\/doi.org\/10.1039\/C9RA02225B","journal-title":"RSC Adv"},{"issue":"6","key":"5417_CR86","doi-asserted-by":"publisher","first-page":"e09782","DOI":"10.1016\/j.heliyon.2022.e09782","volume":"8","author":"W Zhang","year":"2022","unstructured":"Zhang W, Taheri-Ledari R, Ganjali F, Afruzi FH, Hajizadeh Z, Saeidirad M et al (2022) Nanoscale bioconjugates: A review of the structural attributes of drug-loaded nanocarrier conjugates for selective cancer therapy. Heliyon 8(6):e09782. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09782","journal-title":"Heliyon"},{"issue":"6","key":"5417_CR87","doi-asserted-by":"publisher","first-page":"10629","DOI":"10.1021\/acsomega.9b01498","volume":"4","author":"A Maleki","year":"2019","unstructured":"Maleki A, Taheri-Ledari R, Rahimi J, Soroushnejad M, Hajizadeh Z (2019) Facile peptide bond formation: effective interplay between isothiazolone rings and silanol groups at silver\/iron oxide nanocomposite surfaces. ACS Omega 4(6):10629\u201310639. https:\/\/doi.org\/10.1021\/acsomega.9b01498","journal-title":"ACS Omega"},{"key":"5417_CR88","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.mtchem.2019.02.004","volume":"13","author":"A Maleki","year":"2019","unstructured":"Maleki A, Niksefat M, Rahimi J, Taheri-Ledari R (2019) Multicomponent synthesis of pyrano[2,3-d]pyrimidine derivatives via a direct one-pot strategy executed by novel designed copperated Fe3O4@polyvinyl alcohol magnetic nanoparticles. Mater Today Chem 13:110\u2013120. https:\/\/doi.org\/10.1016\/j.mtchem.2019.02.004","journal-title":"Mater Today Chem"},{"key":"5417_CR89","doi-asserted-by":"publisher","first-page":"151526","DOI":"10.1016\/j.bbrc.2021.11.079","volume":"754","author":"R Daksh","year":"2025","unstructured":"Daksh R, Mathew MS, Bosco AM, Sojan C, Tom AA, Bojja SL et al (2025) The role of exosomes in diagnosis, pathophysiology, and management of Alzheimer\u2019s disease. Biochem Biophys Res Commun 754:151526. https:\/\/doi.org\/10.1016\/j.bbrc.2021.11.079","journal-title":"Biochem Biophys Res Commun"},{"issue":"19","key":"5417_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910794","volume":"22","author":"HM Soliman","year":"2021","unstructured":"Soliman HM, Ghonaim GA, Gharib SM, Chopra H, Farag AK, Hassanin MH et al (2021) Exosomes in Alzheimer\u2019s disease: from being pathological players to potential diagnostics and therapeutics. Int J Mol Sci 22(19):10794. https:\/\/doi.org\/10.3390\/ijms221910794","journal-title":"Int J Mol Sci"},{"key":"5417_CR91","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.2147\/JIR.S376243","volume":"17","author":"M Sun","year":"2024","unstructured":"Sun M, Chen Z (2024) Unveiling the complex role of exosomes in Alzheimer\u2019s disease. J Inflamm Res 17:3921\u20133948. https:\/\/doi.org\/10.2147\/JIR.S376243","journal-title":"J Inflamm Res"},{"key":"5417_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1209115","volume":"15","author":"T Liang","year":"2023","unstructured":"Liang T, Wu Z, Li J, Wu S, Shi W, Wang L (2023) The emerging double-edged sword role of exosomes in Alzheimer\u2019s disease. Front Aging Neurosci 15:1209115. https:\/\/doi.org\/10.3389\/fnagi.2023.1209115","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"5417_CR93","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s13534-021-00198-5","volume":"11","author":"MW Seo","year":"2021","unstructured":"Seo MW, Park TE (2021) Recent advances with liposomes as drug carriers for treatment of neurodegenerative diseases. Biomed Eng Lett 11(3):211\u2013216. https:\/\/doi.org\/10.1007\/s13534-021-00198-5","journal-title":"Biomed Eng Lett"},{"key":"5417_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2021.105008","volume":"145","author":"M Agrawal","year":"2021","unstructured":"Agrawal M, Prathyusha E, Ahmed H, Dubey SK, Kesharwani P, Singhvi G et al (2021) Biomaterials in treatment of Alzheimer\u2019s disease. Neurochem Int 145:105008. https:\/\/doi.org\/10.1016\/j.neuint.2021.105008","journal-title":"Neurochem Int"},{"issue":"8","key":"5417_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081899","volume":"12","author":"M Mroziak","year":"2024","unstructured":"Mroziak M, Koz\u0142owski G, Ko\u0142odziejczyk W, Pszczo\u0142owska M, Walczak K, Besz\u0142ej JA et al (2024) Dendrimers\u2014novel therapeutic approaches for Alzheimer\u2019s disease. Biomedicines 12(8):1899. https:\/\/doi.org\/10.3390\/biomedicines12081899","journal-title":"Biomedicines"},{"issue":"3","key":"5417_CR96","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3390\/pharmaceutics15030898","volume":"15","author":"C Arbez-Gindre","year":"2023","unstructured":"Arbez-Gindre C, Steele BR, Micha-Screttas M (2023) Dendrimers in Alzheimer\u2019s disease: recent approaches in multi-targeting strategies. Pharmaceutics 15(3):898. https:\/\/doi.org\/10.3390\/pharmaceutics15030898","journal-title":"Pharmaceutics"},{"issue":"10","key":"5417_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19103224","volume":"19","author":"S Al-Azzawi","year":"2018","unstructured":"Al-Azzawi S, Masheta D, Guildford AL, Phillips G, Santin M (2018) Dendrimeric poly(epsilon-lysine) delivery systems for the enhanced permeability of flurbiprofen across the blood-brain barrier in Alzheimer\u2019s disease. Int J Mol Sci 19(10):3224. https:\/\/doi.org\/10.3390\/ijms19103224","journal-title":"Int J Mol Sci"},{"issue":"12","key":"5417_CR98","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3390\/biom9120790","volume":"9","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Liu C, Pang Z (2019) Dendrimer-based drug delivery systems for brain targeting. Biomolecules 9(12):790. https:\/\/doi.org\/10.3390\/biom9120790","journal-title":"Biomolecules"},{"issue":"2","key":"5417_CR99","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202101854","volume":"11","author":"S Xiang","year":"2022","unstructured":"Xiang S, Wagner J, L\u00fcckerath T, M\u00fcllen K, Ng DYW, Hedrich J et al (2022) Reversing A\u03b2 fibrillation and inhibiting A\u03b2 primary neuronal cell toxicity using amphiphilic polyphenylene dendrons. Adv Healthc Mater 11(2):2101854. https:\/\/doi.org\/10.1002\/adhm.202101854","journal-title":"Adv Healthc Mater"},{"issue":"7","key":"5417_CR100","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.addr.2012.01.002","volume":"64","author":"T Patel","year":"2012","unstructured":"Patel T, Zhou J, Piepmeier JM, Saltzman WM (2012) Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev 64(7):701\u2013705. https:\/\/doi.org\/10.1016\/j.addr.2012.01.002","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"5417_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/nano13030574","volume":"13","author":"TM Joseph","year":"2023","unstructured":"Joseph TM, Kar Mahapatra D, Esmaeili A, Piszczyk \u0141, Hasanin MS, Kattali M et al (2023) Nanoparticles: taking a unique position in medicine. Nanomaterials 13(3):574. https:\/\/doi.org\/10.3390\/nano13030574","journal-title":"Nanomaterials"},{"issue":"1","key":"5417_CR102","doi-asserted-by":"publisher","first-page":"5358","DOI":"10.3402\/nano.v1i0.5358","volume":"1","author":"N Singh","year":"2010","unstructured":"Singh N, Jenkins GJS, Asadi R, Doak SH (2010) Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Reviews 1(1):5358. https:\/\/doi.org\/10.3402\/nano.v1i0.5358","journal-title":"Nano Reviews"},{"key":"5417_CR103","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jconrel.2017.12.025","volume":"270","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Peng Z, Seven ES, Leblanc RM (2018) Crossing the blood\u2013brain barrier with nanoparticles. J Control Release 270:290\u2013303. https:\/\/doi.org\/10.1016\/j.jconrel.2017.12.025","journal-title":"J Control Release"},{"issue":"10","key":"5417_CR104","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.progpolymsci.2010.07.003","volume":"35","author":"JM Oliveira","year":"2010","unstructured":"Oliveira JM, Salgado AJ, Sousa N, Mano JF, Reis RL (2010) Dendrimers and derivatives as a potential therapeutic tool in regenerative medicine strategies\u2014a review. Prog Polym Sci 35(10):1163\u20131194. https:\/\/doi.org\/10.1016\/j.progpolymsci.2010.07.003","journal-title":"Prog Polym Sci"},{"issue":"3","key":"5417_CR105","doi-asserted-by":"publisher","first-page":"e287","DOI":"10.1002\/mco2.287","volume":"4","author":"Q Si","year":"2023","unstructured":"Si Q, Wu L, Pang D, Jiang P (2023) Exosomes in brain diseases: pathogenesis and therapeutic targets. MedComm (Beijing) 4(3):e287. https:\/\/doi.org\/10.1002\/mco2.287","journal-title":"MedComm (Beijing)"},{"issue":"1","key":"5417_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-020-00407-7","volume":"15","author":"T Guo","year":"2020","unstructured":"Guo T, Zhang D, Zeng Y, Huang TY, Xu H, Zhao Y (2020) Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer\u2019s disease. Mol Neurodegener 15(1):1\u201322. https:\/\/doi.org\/10.1186\/s13024-020-00407-7","journal-title":"Mol Neurodegener"},{"issue":"1","key":"5417_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-01234-9","volume":"9","author":"J Zhang","year":"2024","unstructured":"Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L (2024) Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther 9(1):1\u201329. https:\/\/doi.org\/10.1038\/s41392-024-01234-9","journal-title":"Signal Transduct Target Ther"},{"key":"5417_CR108","doi-asserted-by":"publisher","first-page":"130559","DOI":"10.1016\/j.bbagen.2023.130559","volume":"3","author":"A Panghal","year":"1868","unstructured":"Panghal A (1868) Flora SJS (2024) Nanotechnology in the diagnostic and therapy for Alzheimer\u2019s disease. Biochim Biophys Acta Gen Subj 3:130559. https:\/\/doi.org\/10.1016\/j.bbagen.2023.130559","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"1","key":"5417_CR109","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4103\/1673-5374.363828","volume":"19","author":"J Chu","year":"2023","unstructured":"Chu J, Zhang W, Liu Y, Gong B, Ji W, Yin T et al (2023) Biomaterials-based anti-inflammatory treatment strategies for Alzheimer\u2019s disease. Neural Regen Res 19(1):100\u2013108. https:\/\/doi.org\/10.4103\/1673-5374.363828","journal-title":"Neural Regen Res"},{"key":"5417_CR110","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jconrel.2017.04.038","volume":"258","author":"S Mancini","year":"2017","unstructured":"Mancini S, Balducci C, Micotti E, Tolomeo D, Forloni G, Masserini M et al (2017) Multifunctional liposomes delay phenotype progression and prevent memory impairment in a presymptomatic stage mouse model of Alzheimer disease. J Control Release 258:121\u2013129. https:\/\/doi.org\/10.1016\/j.jconrel.2017.04.038","journal-title":"J Control Release"},{"issue":"7","key":"5417_CR111","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","volume":"9","author":"F Mangialasche","year":"2010","unstructured":"Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M (2010) Alzheimer\u2019s disease: clinical trials and drug development. Lancet Neurol 9(7):702\u2013716. https:\/\/doi.org\/10.1016\/S1474-4422(10)70119-8","journal-title":"Lancet Neurol"},{"issue":"5","key":"5417_CR112","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006270","volume":"2","author":"C Haass","year":"2012","unstructured":"Haass C, Kaether C, Thinakaran G, Sisodia S (2012) Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med 2(5):a006270. https:\/\/doi.org\/10.1101\/cshperspect.a006270","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"5417_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2012.10","volume":"1","author":"S Li","year":"2012","unstructured":"Li S, Liu Z, Ji F, Xiao Z, Wang M, Peng Y et al (2012) Delivery of quantum dot-siRNA nanoplexes in SK-N-SH cells for BACE1 gene silencing and intracellular imaging. Mol Ther Nucleic Acids 1(4):e20. https:\/\/doi.org\/10.1038\/mtna.2012.10","journal-title":"Mol Ther Nucleic Acids"},{"issue":"5","key":"5417_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2015.14","volume":"4","author":"R Shyam","year":"2015","unstructured":"Shyam R, Ren Y, Lee J, Braunstein KE, Mao HQ, Wong PC (2015) Intraventricular delivery of siRNA nanoparticles to the central nervous system. Mol Ther Nucleic Acids 4(5):e242. https:\/\/doi.org\/10.1038\/mtna.2015.14","journal-title":"Mol Ther Nucleic Acids"},{"key":"5417_CR115","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.brainres.2012.09.029","volume":"1490","author":"Y Liu","year":"2012","unstructured":"Liu Y, Liu Z, Wang Y, Liang YR, Wen X, Hu J et al (2012) Investigation of the performance of PEG-PEI\/ROCK-II-siRNA complexes for Alzheimer\u2019s disease in vitro. Brain Res 1490:43\u201351. https:\/\/doi.org\/10.1016\/j.brainres.2012.09.029","journal-title":"Brain Res"},{"key":"5417_CR116","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.neuint.2017.05.005","volume":"108","author":"S Sharma","year":"2017","unstructured":"Sharma S, Nehru B, Saini A (2017) Inhibition of Alzheimer\u2019s amyloid-beta aggregation in vitro by carbenoxolone: insight into mechanism of action. Neurochem Int 108:481\u2013493. https:\/\/doi.org\/10.1016\/j.neuint.2017.05.005","journal-title":"Neurochem Int"},{"issue":"2","key":"5417_CR117","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1021\/acsomega.8b03310","volume":"4","author":"Q Huang","year":"2019","unstructured":"Huang Q, Zhao Q, Peng J, Yu Y, Wang C, Zou Y et al (2019) Peptide-polyphenol (KLVFF\/EGCG) binary modulators for inhibiting aggregation and neurotoxicity of amyloid-\u03b2 peptide. ACS Omega 4(2):4233\u20134242. https:\/\/doi.org\/10.1021\/acsomega.8b03310","journal-title":"ACS Omega"},{"issue":"42","key":"5417_CR118","doi-asserted-by":"publisher","first-page":"14022","DOI":"10.1523\/JNEUROSCI.1744-14.2014","volume":"34","author":"C Balducci","year":"2014","unstructured":"Balducci C, Mancini S, Minniti S, La Vitola P, Zotti M, Sancini G et al (2014) Multifunctional liposomes reduce brain \u03b2-amyloid burden and ameliorate memory impairment in Alzheimer\u2019s disease mouse models. J Neurosci 34(42):14022\u201314031. https:\/\/doi.org\/10.1523\/JNEUROSCI.1744-14.2014","journal-title":"J Neurosci"},{"issue":"32","key":"5417_CR119","doi-asserted-by":"publisher","first-page":"19141","DOI":"10.1073\/pnas.2002016117","volume":"117","author":"D Gonzalez-Carter","year":"2020","unstructured":"Gonzalez-Carter D, Liu X, Tockary TA, Dirisala A, Toh K, Anraku Y et al (2020) Targeting nanoparticles to the brain by exploiting the blood brain barrier impermeability to selectively label the brain endothelium. Proc Natl Acad Sci U S A 117(32):19141\u201319150. https:\/\/doi.org\/10.1073\/pnas.2002016117","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"5417_CR120","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1021\/acs.bioconjchem.2c00168","volume":"33","author":"CG Barracchia","year":"2022","unstructured":"Barracchia CG, Parolini F, Volpe A, Gori D, Munari F, Capaldi S et al (2022) Camouflaged fluorescent silica nanoparticles target aggregates and condensates of the amyloidogenic protein tau. Bioconjug Chem 33(7):1261\u20131268. https:\/\/doi.org\/10.1021\/acs.bioconjchem.2c00168","journal-title":"Bioconjug Chem"},{"issue":"2","key":"5417_CR121","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3892\/mmr.2013.1545","volume":"8","author":"FL Yan","year":"2013","unstructured":"Yan FL, Han GL, Wu GJ (2013) Cytotoxic role of advanced glycation end-products in PC12 cells treated with \u03b2-amyloid peptide. Mol Med Rep 8(2):367\u2013372. https:\/\/doi.org\/10.3892\/mmr.2013.1545","journal-title":"Mol Med Rep"},{"issue":"52","key":"5417_CR122","doi-asserted-by":"publisher","first-page":"2403980","DOI":"10.1002\/smll.202403980","volume":"20","author":"Q Guo","year":"2024","unstructured":"Guo Q, Wang T, Qian C, Wang X (2024) Redox oxygen species-responsive nanotheranostics with dual-channel fluorescent turn-on for early diagnosis and targeted therapy of Alzheimer\u2019s disease. Small 20(52):2403980. https:\/\/doi.org\/10.1002\/smll.202403980","journal-title":"Small"},{"issue":"5","key":"5417_CR123","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.freeradbiomed.2011.05.001","volume":"51","author":"M Dumont","year":"2011","unstructured":"Dumont M, Beal MF (2011) Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic Biol Med 51(5):1014\u20131026. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2011.05.001","journal-title":"Free Radic Biol Med"},{"key":"5417_CR124","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/7934442","volume":"2022","author":"AT Aborode","year":"2022","unstructured":"Aborode AT, Pustake M, Awuah WA, Alwerdani M, Shah P, Yarlagadda R et al (2022) Targeting oxidative stress mechanisms to treat Alzheimer\u2019s and Parkinson\u2019s disease: a critical review. Oxid Med Cell Longev 2022:7934442. https:\/\/doi.org\/10.1155\/2022\/7934442","journal-title":"Oxid Med Cell Longev"},{"issue":"7","key":"5417_CR125","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/archneurol.2011.2425","volume":"69","author":"DR Galasko","year":"2012","unstructured":"Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA et al (2012) Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 69(7):836\u2013841. https:\/\/doi.org\/10.1001\/archneurol.2011.2425","journal-title":"Arch Neurol"},{"issue":"4","key":"5417_CR126","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.apsb.2022.01.015","volume":"12","author":"X He","year":"2022","unstructured":"He X, Wang X, Yang L, Yang Z, Yu W, Wang Y et al (2022) Intelligent lesion blood\u2013brain barrier targeting nano-missiles for Alzheimer\u2019s disease treatment by anti-neuroinflammation and neuroprotection. Acta Pharm Sin B 12(4):1987\u20131999. https:\/\/doi.org\/10.1016\/j.apsb.2022.01.015","journal-title":"Acta Pharm Sin B"},{"key":"5417_CR127","doi-asserted-by":"publisher","first-page":"180","DOI":"10.34133\/research.0180","volume":"6","author":"Q Huang","year":"2023","unstructured":"Huang Q, Jiang C, Xia X, Wang Y, Yan C, Wang X et al (2023) Pathological BBB crossing melanin-like nanoparticles as metal-ion chelators and neuroinflammation regulators against Alzheimer\u2019s disease. Research 6:180. https:\/\/doi.org\/10.34133\/research.0180","journal-title":"Research"},{"key":"5417_CR128","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jconrel.2023.04.001","volume":"360","author":"N Song","year":"2023","unstructured":"Song N, Sun S, Chen K, Wang Y, Wang H, Meng J et al (2023) Emerging nanotechnology for Alzheimer\u2019s disease: from detection to treatment. J Control Release 360:392\u2013417. https:\/\/doi.org\/10.1016\/j.jconrel.2023.04.001","journal-title":"J Control Release"},{"issue":"9","key":"5417_CR129","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.3390\/pharmaceutics15092316","volume":"15","author":"CIP Chaparro","year":"2023","unstructured":"Chaparro CIP, Sim\u00f5es BT, Borges JP, Castanho MARB, Soares PIP, Neves V (2023) A promising approach: magnetic nanosystems for Alzheimer\u2019s disease theranostics. Pharmaceutics 15(9):2316. https:\/\/doi.org\/10.3390\/pharmaceutics15092316","journal-title":"Pharmaceutics"},{"issue":"8","key":"5417_CR130","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.drudis.2021.05.019","volume":"26","author":"R Shukla","year":"2021","unstructured":"Shukla R, Singh A, Handa M, Flora SJS, Kesharwani P (2021) Nanotechnological approaches for targeting amyloid-\u03b2 aggregation with potential for neurodegenerative disease therapy and diagnosis. Drug Discov Today 26(8):1972\u20131979. https:\/\/doi.org\/10.1016\/j.drudis.2021.05.019","journal-title":"Drug Discov Today"},{"issue":"2","key":"5417_CR131","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2174\/1381612827666210305150203","volume":"28","author":"P Tripathi","year":"2021","unstructured":"Tripathi P, Shukla P, Bieberich E (2021) Theranostic applications of nanomaterials in Alzheimer\u2019s disease: a multifunctional approach. Curr Pharm Des 28(2):116\u2013132. https:\/\/doi.org\/10.2174\/1381612827666210305150203","journal-title":"Curr Pharm Des"},{"issue":"2","key":"5417_CR132","doi-asserted-by":"publisher","first-page":"51","DOI":"10.62347\/QHVI3317","volume":"14","author":"D Rafieezadeh","year":"2025","unstructured":"Rafieezadeh D, Sabeti G, Khalaji A, Mohammadi H (2025) Advances in nanotechnology for targeted drug delivery in neurodegenerative diseases. Am J Neurodegener Dis 14(2):51\u201357","journal-title":"Am J Neurodegener Dis"},{"issue":"1","key":"5417_CR133","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1023\/A:1006997100077","volume":"20","author":"U Kniesel","year":"2000","unstructured":"Kniesel U, Wolburg H (2000) Tight junctions of the blood-brain barrier. Cell Mol Neurobiol 20(1):57\u201376. https:\/\/doi.org\/10.1023\/A:1006997100077","journal-title":"Cell Mol Neurobiol"},{"key":"5417_CR134","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3389\/fnins.2018.01019","volume":"12","author":"VM Pulgar","year":"2019","unstructured":"Pulgar VM (2019) Transcytosis to cross the blood brain barrier, new advancements and challenges. Front Neurosci 12:1019. https:\/\/doi.org\/10.3389\/fnins.2018.01019","journal-title":"Front Neurosci"},{"issue":"2","key":"5417_CR135","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jconrel.2011.10.031","volume":"161","author":"S Wohlfart","year":"2012","unstructured":"Wohlfart S, Gelperina S, Kreuter J (2012) Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release 161(2):264\u2013273. https:\/\/doi.org\/10.1016\/j.jconrel.2011.10.031","journal-title":"J Control Release"},{"issue":"9","key":"5417_CR136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024438","volume":"6","author":"T dos Santos","year":"2011","unstructured":"dos Santos T, Varela J, Lynch I, Salvati A, Dawson KA (2011) Effects of transport inhibitors on the cellular uptake of carboxylated polystyrene nanoparticles in different cell lines. PLoS ONE 6(9):e24438. https:\/\/doi.org\/10.1371\/journal.pone.0024438","journal-title":"PLoS ONE"},{"issue":"7323","key":"5417_CR137","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nature09522","volume":"468","author":"A Armulik","year":"2010","unstructured":"Armulik A, Genov\u00e9 G, M\u00e4e M, Nisancioglu MH, Wallgard E, Niaudet C et al (2010) Pericytes regulate the blood-brain barrier. Nature 468(7323):557\u2013561. https:\/\/doi.org\/10.1038\/nature09522","journal-title":"Nature"},{"issue":"18","key":"5417_CR138","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1016\/j.biomaterials.2011.02.051","volume":"32","author":"H Xin","year":"2011","unstructured":"Xin H, Jiang X, Gu J, Sha X, Chen L, Law K et al (2011) Angiopep-conjugated poly(ethylene glycol)-co-poly(\u03b5-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 32(18):4293\u20134305. https:\/\/doi.org\/10.1016\/j.biomaterials.2011.02.051","journal-title":"Biomaterials"},{"issue":"Pt A","key":"5417_CR139","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk JS, Xu Q, Kim N, Hanes J, Ensign LM (2016) PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 99(Pt A):28\u201351. https:\/\/doi.org\/10.1016\/j.addr.2015.09.012","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"5417_CR140","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.molimm.2005.02.006","volume":"43","author":"C Salvador-Morales","year":"2006","unstructured":"Salvador-Morales C, Flahaut E, Sim E, Sloan J, Green MLH, Sim RB (2006) Complement activation and protein adsorption by carbon nanotubes. Mol Immunol 43(3):193\u2013201. https:\/\/doi.org\/10.1016\/j.molimm.2005.02.006","journal-title":"Mol Immunol"},{"issue":"4","key":"5417_CR141","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1021\/nn204530w","volume":"6","author":"R Qiao","year":"2012","unstructured":"Qiao R, Jia Q, H\u00fcwel S, Xia R, Liu T, Gao F et al (2012) Receptor-mediated delivery of magnetic nanoparticles across the blood-brain barrier. ACS Nano 6(4):3304\u20133310. https:\/\/doi.org\/10.1021\/nn204530w","journal-title":"ACS Nano"},{"issue":"9","key":"5417_CR142","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1021\/acs.chemrev.5b00346","volume":"116","author":"K Ulbrich","year":"2016","unstructured":"Ulbrich K, Hol\u00e1 K, \u0160ubr V, Bakandritsos A, Tu\u010dek J, Zbo\u0159il R (2016) Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches. Chem Rev 116(9):5338\u20135431. https:\/\/doi.org\/10.1021\/acs.chemrev.5b00346","journal-title":"Chem Rev"},{"key":"5417_CR143","doi-asserted-by":"crossref","unstructured":"Soleymani S, Doroudian M, Soezi M, Beladi A, Asgari K, Mobarakshahi A et al (2024) Engendered nanoparticles for treatment of brain tumors. Oncol Res 33(1):15. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC11671406\/. Accessed 10 Aug 2025","DOI":"10.32604\/or.2024.053069"},{"issue":"23","key":"5417_CR144","doi-asserted-by":"publisher","first-page":"10971","DOI":"10.1021\/acs.nanolett.3c03222","volume":"23","author":"GC Tracy","year":"2023","unstructured":"Tracy GC, Huang KY, Hong YT, Ding S, Noblet HA, Lim KH et al (2023) Intracerebral nanoparticle transport facilitated by Alzheimer pathology and age. Nano Lett 23(23):10971\u201310982. https:\/\/doi.org\/10.1021\/acs.nanolett.3c03222","journal-title":"Nano Lett"},{"issue":"36","key":"5417_CR145","doi-asserted-by":"publisher","first-page":"8605","DOI":"10.1039\/D3TB01023F","volume":"11","author":"M Aili","year":"2023","unstructured":"Aili M, Zhou K, Zhan J, Zheng H, Luo F (2023) Anti-inflammatory role of gold nanoparticles in the prevention and treatment of Alzheimer\u2019s disease. J Mater Chem B 11(36):8605\u20138621. https:\/\/doi.org\/10.1039\/D3TB01023F","journal-title":"J Mater Chem B"},{"key":"5417_CR146","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.bioactmat.2023.04.017","volume":"24","author":"J Kim","year":"2023","unstructured":"Kim J, Um H, Kim NH, Kim D (2023) Potential Alzheimer\u2019s disease therapeutic nano-platform: discovery of amyloid-beta plaque disaggregating agent and brain-targeted delivery system using porous silicon nanoparticles. Bioact Mater 24:497\u2013506. https:\/\/doi.org\/10.1016\/j.bioactmat.2023.04.017","journal-title":"Bioact Mater"},{"key":"5417_CR147","doi-asserted-by":"crossref","unstructured":"Zhao N, Francis NL, Calvelli HR, Moghe PV (2020) Microglia-targeting nanotherapeutics for neurodegenerative diseases. APL Bioeng 4(3). https:\/\/www.researchgate.net\/publication\/344168667_Microglia-targeting_nanotherapeutics_for_neurodegenerative_diseases. Accessed 10 Aug 2025","DOI":"10.1063\/5.0013178"},{"key":"5417_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.939855","volume":"16","author":"L La Barbera","year":"2022","unstructured":"La Barbera L, Mauri E, D\u2019Amelio M, Gori M (2022) Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer\u2019s disease: current trends and future perspectives. Front Neurosci 16:939855. https:\/\/doi.org\/10.3389\/fnins.2022.939855","journal-title":"Front Neurosci"},{"issue":"10","key":"5417_CR149","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH et al (2021) The amyloid-\u03b2 pathway in Alzheimer\u2019s disease. Mol Psychiatry 26(10):5481\u20135503. https:\/\/doi.org\/10.1038\/s41380-021-01249-0","journal-title":"Mol Psychiatry"},{"issue":"10","key":"5417_CR150","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1038\/cdd.2014.72","volume":"21","author":"JM Dowding","year":"2014","unstructured":"Dowding JM, Song W, Bossy K, Karakoti A, Kumar A, Kim A et al (2014) Cerium oxide nanoparticles protect against A\u03b2-induced mitochondrial fragmentation and neuronal cell death. Cell Death Differ 21(10):1622\u20131632. https:\/\/doi.org\/10.1038\/cdd.2014.72","journal-title":"Cell Death Differ"},{"key":"5417_CR151","doi-asserted-by":"crossref","unstructured":"Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5(4):505\u201315. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2663893\/. Accessed 10 Aug 2025","DOI":"10.1021\/mp800051m"},{"issue":"2","key":"5417_CR152","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3390\/futurepharma4020020","volume":"4","author":"JP Capela","year":"2024","unstructured":"Capela JP, Schifano F, Krsek A, Baticic L (2024) Nanotechnology-driven therapeutic innovations in neurodegenerative disorders: a focus on Alzheimer\u2019s and Parkinson\u2019s disease. Future Pharmacol 4(2):352\u2013379. https:\/\/doi.org\/10.3390\/futurepharma4020020","journal-title":"Future Pharmacol"},{"key":"5417_CR153","doi-asserted-by":"publisher","first-page":"1112435","DOI":"10.3389\/fnins.2023.1112435","volume":"17","author":"N Liu","year":"2023","unstructured":"Liu N, Ruan J, Li H, Fu J (2023) Nanoparticles loaded with natural medicines for the treatment of Alzheimer\u2019s disease. Front Neurosci 17:1112435. https:\/\/doi.org\/10.3389\/fnins.2023.1112435","journal-title":"Front Neurosci"},{"key":"5417_CR154","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.879114","volume":"14","author":"H Chopra","year":"2022","unstructured":"Chopra H, Bibi S, Singh I, Kamal MA, Islam F, Alhumaydhi FA et al (2022) Nanomedicines in the management of Alzheimer\u2019s disease: current view and future prospects. Front Aging Neurosci 14:879114. https:\/\/doi.org\/10.3389\/fnagi.2022.879114","journal-title":"Front Aging Neurosci"},{"key":"5417_CR155","doi-asserted-by":"crossref","unstructured":"Afzal O, Altamimi ASA, Nadeem MS, Alzarea SI, Almalki WH, Tariq A et al (2022) Nanoparticles in drug delivery: From history to therapeutic applications. Nanomaterials 12(24):4494. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9781272\/. Accessed 10 Aug 2025","DOI":"10.3390\/nano12244494"},{"key":"5417_CR156","doi-asserted-by":"crossref","unstructured":"Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J (2013) The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 9(1):1\u201314. https:\/\/pubmed.ncbi.nlm.nih.gov\/22684017\/. Accessed 10 Aug 2025","DOI":"10.1016\/j.nano.2012.05.013"},{"issue":"6","key":"5417_CR157","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med 8(6):595\u2013608. https:\/\/doi.org\/10.15252\/emmm.201606210","journal-title":"EMBO Mol Med"},{"issue":"2","key":"5417_CR158","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41583-018-0112-7","volume":"20","author":"CM Henstridge","year":"2019","unstructured":"Henstridge CM, Hyman BT, Spires-Jones TL (2019) Beyond the neuron\u2014cellular interactions early in Alzheimer disease pathogenesis. Nat Rev Neurosci 20(2):94\u2013108. https:\/\/doi.org\/10.1038\/s41583-018-0112-7","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"5417_CR159","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.cell.2015.10.067","volume":"163","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV (2015) Establishment and dysfunction of the blood-brain barrier. Cell 163(5):1064\u20131078. https:\/\/doi.org\/10.1016\/j.cell.2015.10.067","journal-title":"Cell"},{"key":"5417_CR160","doi-asserted-by":"crossref","unstructured":"Pinheiro RGR, Coutinho AJ, Pinheiro M, Neves AR (2021) Nanoparticles for targeted brain drug delivery: What do we know? Int J Mol Sci 22(21):11654. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8584083\/. Accessed 10 Aug 2025","DOI":"10.3390\/ijms222111654"},{"issue":"11","key":"5417_CR161","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1084\/jem.20171406","volume":"214","author":"A Montagne","year":"2017","unstructured":"Montagne A, Zhao Z, Zlokovic BV (2017) Alzheimer\u2019s disease: a matter of blood-brain barrier dysfunction? J Exp Med 214(11):3151\u20133169. https:\/\/doi.org\/10.1084\/jem.20171406","journal-title":"J Exp Med"},{"issue":"3","key":"5417_CR162","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","volume":"14","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Sagare AP, Zlokovic BV (2018) Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol 14(3):133\u2013150. https:\/\/doi.org\/10.1038\/nrneurol.2017.188","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"5417_CR163","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3109\/1061186X.2010.499525","volume":"19","author":"K Ulbrich","year":"2011","unstructured":"Ulbrich K, Knobloch T, Kreuter J (2011) Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J Drug Target 19(2):125\u2013132. https:\/\/doi.org\/10.3109\/1061186X.2010.499525","journal-title":"J Drug Target"},{"key":"5417_CR164","doi-asserted-by":"crossref","unstructured":"Zhu Y, Xu H, Yu C, Jiang W, Hou X, Ma M et al (2025) Polymers for the treatment of Alzheimer\u2019s disease. Front Pharmacol 16:1512941. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC11813879\/. Accessed 10 Aug 2025","DOI":"10.3389\/fphar.2025.1512941"},{"key":"5417_CR165","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/bs.pbr.2018.11.006","volume":"245","author":"G Tosi","year":"2019","unstructured":"Tosi G, Pederzoli F, Belletti D, Vandelli MA, Forni F, Duskey JT et al (2019) Nanomedicine in Alzheimer\u2019s disease: amyloid beta targeting strategy. Prog Brain Res 245:57\u201388. https:\/\/doi.org\/10.1016\/bs.pbr.2018.11.006","journal-title":"Prog Brain Res"},{"issue":"2","key":"5417_CR166","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ejpb.2008.10.009","volume":"71","author":"K Ulbrich","year":"2009","unstructured":"Ulbrich K, Hekmatara T, Herbert E, Kreuter J (2009) Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 71(2):251\u2013256. https:\/\/doi.org\/10.1016\/j.ejpb.2008.10.009","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"5417_CR167","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/17435390.2024.9876543","volume":"19","author":"DB Tripathy","year":"2025","unstructured":"Tripathy DB, Pradhan S, Gupta A, Agarwal P (2025) Nanoparticles induced neurotoxicity. Nanotoxicology 19(3):325\u2013352. https:\/\/doi.org\/10.1080\/17435390.2024.9876543","journal-title":"Nanotoxicology"},{"key":"5417_CR168","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.742065","volume":"15","author":"L Muzio","year":"2021","unstructured":"Muzio L, Viotti A, Martino G (2021) Microglia in neuroinflammation and neurodegeneration: from understanding to therapy. Front Neurosci 15:742065. https:\/\/doi.org\/10.3389\/fnins.2021.742065","journal-title":"Front Neurosci"},{"key":"5417_CR169","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-3-211-99374-5_58","volume":"106","author":"HS Sharma","year":"2010","unstructured":"Sharma HS, Hussain S, Schlager J, Ali SF, Sharma A (2010) Influence of nanoparticles on blood-brain barrier permeability and brain edema formation in rats. Acta Neurochir Suppl 106:359\u2013364. https:\/\/doi.org\/10.1007\/978-3-211-99374-5_58","journal-title":"Acta Neurochir Suppl"},{"key":"5417_CR170","doi-asserted-by":"crossref","unstructured":"Kyriakides TR, Raj A, Tseng TH, Xiao H, Nguyen R, Mohammed FS et al (2021) Biocompatibility of nanomaterials and their immunological properties. Biomed Mater 16(4):045009. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8357854\/. Accessed 10 Aug 2025","DOI":"10.1088\/1748-605X\/abe5fa"},{"key":"5417_CR171","doi-asserted-by":"crossref","unstructured":"Wang Y, Li P, Kong L (2013) Chitosan-modified PLGA nanoparticles with versatile surface for improved drug delivery. AAPS PharmSciTech 14(2):585\u201397. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3665987\/. Accessed 10 Aug 2025","DOI":"10.1208\/s12249-013-9943-3"},{"key":"5417_CR172","doi-asserted-by":"crossref","unstructured":"Suk JS, Xu Q, Kim N, Hanes J, Ensign LM (2015) PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 99(Pt A):28\u201351. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4798869\/. Accessed 10 Aug 2025","DOI":"10.1016\/j.addr.2015.09.012"},{"issue":"180","key":"5417_CR173","doi-asserted-by":"publisher","first-page":"114079","DOI":"10.1016\/j.addr.2021.01.006","volume":"1","author":"D Shi","year":"2021","unstructured":"Shi D, Beasock D, Fessler A, Szebeni J, Ljubimova JY, Afonin KA et al (2021) To PEGylate or not to PEGylate: immunological properties of nanomedicine\u2019s most popular component, poly(ethylene) glycol and its alternatives. Adv Drug Deliv Rev 1(180):114079. https:\/\/doi.org\/10.1016\/j.addr.2021.01.006","journal-title":"Adv Drug Deliv Rev"},{"issue":"24","key":"5417_CR174","doi-asserted-by":"publisher","first-page":"10748","DOI":"10.1039\/d1nr02065j","volume":"13","author":"L Shi","year":"2021","unstructured":"Shi L, Zhang J, Zhao M, Tang S, Cheng X, Zhang W et al (2021) Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery. Nanoscale 13(24):10748\u201310764. https:\/\/doi.org\/10.1039\/d1nr02065j","journal-title":"Nanoscale"},{"issue":"1","key":"5417_CR175","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3233\/ADR-220109","volume":"7","author":"A Behera","year":"2023","unstructured":"Behera A, Sa N, Pradhan SP, Swain S, Sahu PK (2023) Metal nanoparticles in Alzheimer\u2019s disease. J Alzheimers Dis Rep 7(1):791. https:\/\/doi.org\/10.3233\/ADR-220109","journal-title":"J Alzheimers Dis Rep"},{"issue":"3","key":"5417_CR176","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.toxlet.2008.12.013","volume":"185","author":"V Sharma","year":"2009","unstructured":"Sharma V, Shukla RK, Saxena N, Parmar D, Das M, Dhawan A (2009) DNA damaging potential of zinc oxide nanoparticles in human epidermal cells. Toxicol Lett 185(3):211\u2013218. https:\/\/doi.org\/10.1016\/j.toxlet.2008.12.013","journal-title":"Toxicol Lett"},{"issue":"301","key":"5417_CR177","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jhazmat.2015.08.009","volume":"15","author":"C Krishnaraj","year":"2015","unstructured":"Krishnaraj C, Harper SL, Yun SI (2015) In vivo toxicological assessment of biologically synthesized silver nanoparticles in adult zebrafish (Danio rerio). J Hazard Mater 15(301):480\u2013489. https:\/\/doi.org\/10.1016\/j.jhazmat.2015.08.009","journal-title":"J Hazard Mater"},{"issue":"3","key":"5417_CR178","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jtumed.2024.04.006","volume":"19","author":"YSM Elmahboub","year":"2024","unstructured":"Elmahboub YSM, Elkordy AA (2024) Polymeric nanoparticles: A promising strategy for treatment of Alzheimer\u2019s disease. J Taibah Univ Med Sci 19(3):549\u2013562. https:\/\/doi.org\/10.1016\/j.jtumed.2024.04.006","journal-title":"J Taibah Univ Med Sci"},{"issue":"3","key":"5417_CR179","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1007\/s12011-020-02225-0","volume":"199","author":"J Hou","year":"2021","unstructured":"Hou J, Zhao L, Tang H, He X, Ye G, Shi F et al (2021) Silver nanoparticles induced oxidative stress and mitochondrial injuries mediated autophagy in HC11 cells through Akt\/AMPK\/mTOR pathway. Biol Trace Elem Res 199(3):1062\u20131073. https:\/\/doi.org\/10.1007\/s12011-020-02225-0","journal-title":"Biol Trace Elem Res"},{"issue":"14","key":"5417_CR180","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/j.biomaterials.2009.01.054","volume":"30","author":"MS Cartiera","year":"2009","unstructured":"Cartiera MS, Johnson KM, Rajendran V, Caplan MJ, Saltzman WM (2009) The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials 30(14):2790\u20132798. https:\/\/doi.org\/10.1016\/j.biomaterials.2009.01.054","journal-title":"Biomaterials"},{"issue":"4","key":"5417_CR181","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1021\/mp800051m","volume":"5","author":"F Alexis","year":"2008","unstructured":"Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5(4):505\u2013515. https:\/\/doi.org\/10.1021\/mp800051m","journal-title":"Mol Pharm"},{"key":"5417_CR182","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1591438","volume":"16","author":"K Wang","year":"2025","unstructured":"Wang K, Yang R, Li J, Wang H, Wan L, He J (2025) Nanocarrier-based targeted drug delivery for Alzheimer\u2019s disease: addressing neuroinflammation and enhancing clinical translation. Front Pharmacol 16:1591438. https:\/\/doi.org\/10.3389\/fphar.2025.1591438","journal-title":"Front Pharmacol"},{"issue":"12","key":"5417_CR183","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/nnano.2012.207","volume":"7","author":"MP Monopoli","year":"2012","unstructured":"Monopoli MP, \u00c5berg C, Salvati A, Dawson KA (2012) Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol 7(12):779\u2013786. https:\/\/doi.org\/10.1038\/nnano.2012.207","journal-title":"Nat Nanotechnol"},{"issue":"6","key":"5417_CR184","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1039\/d2lc01005a","volume":"23","author":"G Bashiri","year":"2023","unstructured":"Bashiri G, Padilla MS, Swingle KL, Shepherd SJ, Mitchell MJ, Wang K (2023) Nanoparticle protein corona: from structure and function to therapeutic targeting. Lab Chip 23(6):1432\u20131445. https:\/\/doi.org\/10.1039\/d2lc01005a","journal-title":"Lab Chip"},{"issue":"23","key":"5417_CR185","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S et al (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 370(23):311\u2013321. https:\/\/doi.org\/10.1056\/NEJMoa1312889","journal-title":"N Engl J Med"},{"issue":"5","key":"5417_CR186","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-016-1574-z","volume":"131","author":"LM Tai","year":"2016","unstructured":"Tai LM, Thomas R, Marottoli FM, Koster KP, Kanekiyo T, Morris AWJ et al (2016) The role of APOE in cerebrovascular dysfunction. Acta Neuropathol 131(5):709\u2013723. https:\/\/doi.org\/10.1007\/s00401-016-1574-z","journal-title":"Acta Neuropathol"},{"issue":"6","key":"5417_CR187","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11061752","volume":"11","author":"SN Mir Najib Ullah","year":"2023","unstructured":"Mir Najib Ullah SN, Afzal O, Altamimi ASA, Ather H, Sultana S, Almalki WH et al (2023) Nanomedicine in the management of Alzheimer\u2019s disease: state-of-the-art. Biomedicines 11(6):1752. https:\/\/doi.org\/10.3390\/biomedicines11061752","journal-title":"Biomedicines"},{"issue":"10","key":"5417_CR188","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","volume":"33","author":"D Bobo","year":"2016","unstructured":"Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR (2016) Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res 33(10):2373\u20132387. https:\/\/doi.org\/10.1007\/s11095-016-1958-5","journal-title":"Pharm Res"},{"key":"5417_CR189","doi-asserted-by":"publisher","unstructured":"Cummings J, Lee G, Zhong K, Fonseca J, Taghva K (2021) Alzheimer\u2019s disease drug development pipeline: 2021. Alzheimers Dement (N Y). 7(1):e12179 https:\/\/doi.org\/10.1002\/trc2.12179","DOI":"10.1002\/trc2.12179"},{"issue":"1","key":"5417_CR190","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41380-019-0362-8","volume":"25","author":"J Penney","year":"2019","unstructured":"Penney J, Ralvenius WT, Tsai LH (2019) Modeling Alzheimer\u2019s disease with iPSC-derived brain cells. Mol Psychiatry 25(1):148. https:\/\/doi.org\/10.1038\/s41380-019-0362-8","journal-title":"Mol Psychiatry"},{"issue":"8","key":"5417_CR191","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1039\/D2SM01306E","volume":"19","author":"N Kambar","year":"2023","unstructured":"Kambar N, Leal C (2023) Microfluidic synthesis of multilayered lipid\u2013polymer hybrid nanoparticles for the formulation of low solubility drugs. Soft Matter 19(8):1596\u20131606. https:\/\/doi.org\/10.1039\/D2SM01306E","journal-title":"Soft Matter"},{"issue":"13","key":"5417_CR192","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202300145","volume":"14","author":"YT Goo","year":"2025","unstructured":"Goo YT, Grigoriev V, Korzun T, Sharma KS, Singh P, Taratula OR et al (2025) Blood-brain barrier-penetrating nanocarriers enable microglial-specific drug delivery in hypothalamic neuroinflammation. Adv Healthc Mater 14(13):e2300145. https:\/\/doi.org\/10.1002\/adhm.202300145","journal-title":"Adv Healthc Mater"},{"issue":"4","key":"5417_CR193","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3233\/JAD-2004-6406","volume":"6","author":"L Baum","year":"2004","unstructured":"Baum L, Ng A (2004) Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer\u2019s disease animal models. J Alzheimers Dis 6(4):367\u2013377. https:\/\/doi.org\/10.3233\/JAD-2004-6406","journal-title":"J Alzheimers Dis"},{"key":"5417_CR194","unstructured":"Study Details | A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer\u2019s Disease. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT00164749. Accessed 7 Aug 2025"},{"issue":"3","key":"5417_CR195","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1208\/s12248-008-9051-1","volume":"10","author":"F Herv\u00e9","year":"2008","unstructured":"Herv\u00e9 F, Ghinea N, Scherrmann JM (2008) CNS delivery via adsorptive transcytosis. AAPS J 10(3):455\u2013472. https:\/\/doi.org\/10.1208\/s12248-008-9051-1","journal-title":"AAPS J"},{"key":"5417_CR196","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2020.100860","volume":"59","author":"Z Huang","year":"2020","unstructured":"Huang Z, Wong LW, Su Y, Huang X, Wang N, Chen H et al (2020) Blood-brain barrier integrity in the pathogenesis of Alzheimer\u2019s disease. Front Neuroendocrinol 59:100860. https:\/\/doi.org\/10.1016\/j.yfrne.2020.100860","journal-title":"Front Neuroendocrinol"},{"key":"5417_CR197","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jconrel.2020.08.033","volume":"328","author":"JM Rabanel","year":"2020","unstructured":"Rabanel JM, Piec PA, Landri S, Patten SA, Ramassamy C (2020) Transport of PEGylated-PLA nanoparticles across a blood brain barrier model, entry into neuronal cells and in vivo brain bioavailability. J Control Release 328:679\u2013695. https:\/\/doi.org\/10.1016\/j.jconrel.2020.08.033","journal-title":"J Control Release"},{"issue":"2","key":"5417_CR198","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2174\/1381612827666220315111214","volume":"28","author":"P Tripathi","year":"2022","unstructured":"Tripathi P, Shukla P, Bieberich E (2022) Theranostic applications of nanomaterials in Alzheimer\u2019s disease: a multifunctional approach. Curr Pharm Des 28(2):116\u2013132. https:\/\/doi.org\/10.2174\/1381612827666220315111214","journal-title":"Curr Pharm Des"},{"issue":"20","key":"5417_CR199","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25204866","volume":"25","author":"E Manek","year":"2020","unstructured":"Manek E, Darvas F, Petroianu GA (2020) Use of biodegradable, chitosan-based nanoparticles in the treatment of Alzheimer\u2019s disease. Molecules 25(20):4866. https:\/\/doi.org\/10.3390\/molecules25204866","journal-title":"Molecules"},{"issue":"21","key":"5417_CR200","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1021\/acschemneuro.4c00513","volume":"15","author":"AK Mahanta","year":"2024","unstructured":"Mahanta AK, Chaulagain B, Trivedi R, Singh J (2024) Mannose-functionalized chitosan-coated PLGA nanoparticles for brain-targeted codelivery of CBD and BDNF for the treatment of Alzheimer\u2019s disease. ACS Chem Neurosci 15(21):3662\u20133674. https:\/\/doi.org\/10.1021\/acschemneuro.4c00513","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"5417_CR201","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1208\/s12248-012-9339-4","volume":"14","author":"N Desai","year":"2012","unstructured":"Desai N (2012) Challenges in development of nanoparticle-based therapeutics. AAPS J 14(2):282\u2013283. https:\/\/doi.org\/10.1208\/s12248-012-9339-4","journal-title":"AAPS J"},{"key":"5417_CR202","doi-asserted-by":"publisher","first-page":"1360302","DOI":"10.3389\/fddrv.2024.1360302","volume":"4","author":"AS Haqqani","year":"2024","unstructured":"Haqqani AS, B\u00e9langer K, Stanimirovic DB (2024) Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria. Front Drug Deliv 4:1360302. https:\/\/doi.org\/10.3389\/fddrv.2024.1360302","journal-title":"Front Drug Deliv"},{"issue":"2","key":"5417_CR203","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20020381","volume":"20","author":"KH Wong","year":"2019","unstructured":"Wong KH, Riaz MK, Xie Y, Zhang X, Liu Q, Chen H et al (2019) Review of current strategies for delivering Alzheimer\u2019s disease drugs across the blood-brain barrier. Int J Mol Sci 20(2):381. https:\/\/doi.org\/10.3390\/ijms20020381","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5417_CR204","doi-asserted-by":"publisher","DOI":"10.1080\/21688370.2016.1153568","volume":"4","author":"AM Grabrucker","year":"2016","unstructured":"Grabrucker AM, Ruozi B, Belletti D, Pederzoli F, Forni F, Vandelli MA et al (2016) Nanoparticle transport across the blood brain barrier. Tissue Barriers 4(1):e1153568. https:\/\/doi.org\/10.1080\/21688370.2016.1153568","journal-title":"Tissue Barriers"},{"key":"5417_CR205","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3389\/fnins.2019.01019","volume":"13","author":"VM Pulgar","year":"2019","unstructured":"Pulgar VM (2019) Transcytosis to cross the blood brain barrier, new advancements and challenges. Front Neurosci 13:1019. https:\/\/doi.org\/10.3389\/fnins.2019.01019","journal-title":"Front Neurosci"},{"key":"5417_CR206","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.2147\/IJN.S107392","volume":"11","author":"DB Vieira","year":"2016","unstructured":"Vieira DB, Gamarra LF (2016) Getting into the brain: liposome-based strategies for effective drug delivery across the blood\u2013brain barrier. Int J Nanomedicine 11:5381\u20135414. https:\/\/doi.org\/10.2147\/IJN.S107392","journal-title":"Int J Nanomedicine"},{"key":"5417_CR207","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1743-8977-7-3","volume":"7","author":"S Bhaskar","year":"2010","unstructured":"Bhaskar S, Tian F, Stoeger T, Kreyling W, de la Fuente JM, Graz\u00fa V et al (2010) Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol 7:3. https:\/\/doi.org\/10.1186\/1743-8977-7-3","journal-title":"Part Fibre Toxicol"},{"key":"5417_CR208","doi-asserted-by":"publisher","first-page":"11357","DOI":"10.2147\/IJN.S430250","volume":"19","author":"G Wilar","year":"2024","unstructured":"Wilar G, Suhandi C, Wathoni N, Fukunaga K, Kawahata I (2024) Nanoparticle-based drug delivery systems enhance treatment of cognitive defects. Int J Nanomedicine 19:11357\u201311378. https:\/\/doi.org\/10.2147\/IJN.S430250","journal-title":"Int J Nanomedicine"},{"issue":"4","key":"5417_CR209","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3390\/pharmaceutics10040218","volume":"10","author":"DM Teleanu","year":"2018","unstructured":"Teleanu DM, Chircov C, Grumezescu AM, Volceanov A, Teleanu RI (2018) Blood-brain delivery methods using nanotechnology. Pharmaceutics 10(4):218. https:\/\/doi.org\/10.3390\/pharmaceutics10040218","journal-title":"Pharmaceutics"},{"issue":"3","key":"5417_CR210","doi-asserted-by":"publisher","DOI":"10.3390\/jfb13030125","volume":"13","author":"N Montegiove","year":"2022","unstructured":"Montegiove N, Calzoni E, Emiliani C, Cesaretti A (2022) Biopolymer nanoparticles for nose-to-brain drug delivery: a new promising approach for the treatment of neurological diseases. J Funct Biomater 13(3):125. https:\/\/doi.org\/10.3390\/jfb13030125","journal-title":"J Funct Biomater"},{"issue":"8","key":"5417_CR211","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26083905","volume":"26","author":"H Xing","year":"2025","unstructured":"Xing H, Yue S, Qin R, Du X, Wu Y, Zhangsun D et al (2025) Recent advances in drug development for Alzheimer\u2019s disease: a comprehensive review. Int J Mol Sci 26(8):3905. https:\/\/doi.org\/10.3390\/ijms26083905","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5417_CR212","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12987-020-00224-7","volume":"17","author":"H Kadry","year":"2020","unstructured":"Kadry H, Noorani B, Cucullo L (2020) A blood\u2013brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS 17(1):69. https:\/\/doi.org\/10.1186\/s12987-020-00224-7","journal-title":"Fluids Barriers CNS"},{"issue":"2","key":"5417_CR213","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jconrel.2012.04.020","volume":"161","author":"T Lammers","year":"2012","unstructured":"Lammers T, Kiessling F, Hennink WE, Storm G (2012) Drug targeting to tumors: principles, pitfalls and (pre-)clinical progress. J Control Release 161(2):175\u2013187. https:\/\/doi.org\/10.1016\/j.jconrel.2012.04.020","journal-title":"J Control Release"},{"key":"5417_CR214","unstructured":"Study Details | Study of APH-1105 in Patients With Mild to Moderate Alzheimer\u2019s Disease. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03806478. Accessed 7 Aug 2025"},{"key":"5417_CR215","unstructured":"Study Details | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer\u2019s Disease (TRAILBLAZER-ALZ 2). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04437511. Accessed 7 Aug 2025"},{"key":"5417_CR216","unstructured":"Study Details | A Study of JNJ-63733657 in Participants With Early Alzheimer\u2019s Disease. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04619420. Accessed 7 Aug 2025"},{"key":"5417_CR217","unstructured":"Study Details | A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer\u2019s Disease (AD). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02670083. Accessed 7 Aug 2025"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05417-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05417-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05417-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T01:57:09Z","timestamp":1763517429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05417-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":217,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5417"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05417-z","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests:"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"75"}}